Results 41 to 50 of about 10,952 (242)

Psychedelics for Moral Bioenhancement in Healthy Individuals—A Violation of the Non-Maleficence Principle?

Psychoactives
Several authors have advanced the idea that psychedelics such as psilocybin might be effective means for achieving moral bioenhancement (MBE). Here, I discuss some reservations on this assertion from both neuropharmacological and bioethical perspectives,
Bor Luen Tang
doaj   +1 more source

Pharmacokinetics and safety of a modified‐release psilocybin formulation: A SAD Phase I trial in normal‐weight and overweight/obese participants

British Journal of Clinical Pharmacology, EarlyView.
Aims This study aimed to evaluate the safety, tolerability and pharmacokinetics of a novel oral modified‐release psilocybin formulation (REL‐P11) in normal‐weight and overweight/obese healthy adults and to assess its suitability for controlled, subperceptual exposure, in light of emerging evidence supporting serotonergic modulation in metabolic ...
Anna Signor, Stefano Comai, Gianfranco Pasut, Franco Folli, Marco Gentilucci, Negar Gharavi, Sofia Raitsin, Thuy Van Nguyen, Marco Pappagallo, Andrea Mattarei, Paolo L. Manfredi, Sara De Martin   +11 more
wiley   +1 more source

Psychedelics: A new era of treatment?

European Psychiatry, 2021
Introduction Psychedelics - including LSD (lysergic acid diethylamide), psilocybin, DMT (N, N-dimethyltryptamine), ayahuasca and mescaline - have an ancient history across various civilizations.
S. Torres
doaj   +1 more source

Understanding Consumption of Illicit Drugs and New Psychoactive Substances in Australia by Triangulating Drug Checking and Wastewater‐Based Epidemiology

Drug Testing and Analysis, EarlyView.
First Australian study combining wastewater‐based epidemiology and drug checking, demonstrating how complementary data sources enhance monitoring of illicit drugs and emerging psychoactive substances during high‐use periods. ABSTRACT Consumption of psychotropic drugs is a major economic and public health challenge in Australia.
Muhammad Usman, Malcolm McLeod, Dhayaalini Nadarajan, Joseph Clokey, Pritesh Prasad, Rory Verhagen, Benjamin Tscharke, Maurizio Quinto, Richard Bade   +8 more
wiley   +1 more source

Attitudes of European psychiatrists on psychedelics: a cross-sectional survey study

Scientific Reports
Research and public interest in psychedelic-assisted psychotherapy (PAP) are growing. This study investigated attitudes toward psychedelics among a diverse and multinational sample of psychiatrists currently working in Europe.
Marija Franka Žuljević, Darko Hren, Dawid Storman, Mariano Kaliterna, Darko Duplančić   +4 more
doaj   +1 more source

Psilocybin as a Transdiagnostic Treatment for Eating Disorders and Comorbid Psychopathology: Implications for Clinical Nosology and Research Directions

International Journal of Eating Disorders, EarlyView.
ABSTRACT Objective Eating disorders (EDs) are characterized by high rates of psychiatric comorbidity and suboptimal treatment outcomes. There remain critical gaps in research, including the exploration of effective transdiagnostic interventions. This forum article examines the potential of psilocybin treatment (PT) as a transdiagnostic intervention for
Elena Koning, Jérémie Richard, Aaron Keshen   +2 more
wiley   +1 more source

Localizing value of ecstatic phenomenon in epilepsy surgery: A systematic review

Epileptic Disorders, EarlyView.
Abstract Objective A systematic review was conducted to synthesize current anatomo‐clinical correlations of ecstatic symptoms in focal epilepsy, aiming to provide evidence‐based guidance for interpreting this ictal semiology during presurgical evaluation.
Mihai Dragos Maliia, Fabrice Bartolomei, Fabienne Picard   +2 more
wiley   +1 more source

Psychedelics as change agents in addiction and mood disorders. [PDF]

, 2017
Research on psychedelics has generated renewed interest over the past decade. Recent pilot studies have shown safety and feasibility of psilocybin, a naturally occurring psychedelic, as a therapeutic tool for treating mood and substance use disorders ...
Garcia-Romeu, Albert
core  

Psychedelic Assisted Psychotherapy for Treating Substance Use Disorders

, 2023
openDespite the rapid growth in the field of mental health, therapists still have relatively limited options when it comes to treating mental disorders. A promising field of study in recent years has been the research conducted on psychedelics.
OZERDEM, DENIZ BORA
core  

Serotonergic psychedelics for depression: What do we know about neurobiological mechanisms of action?

Frontiers in Psychiatry, 2023
IntroductionCurrent treatment options for major depressive disorder (MDD) have limited efficacy and are associated with adverse effects. Recent studies investigating the antidepressant effect of serotonergic psychedelics—also known as classic ...
Muhammad Ishrat Husain, Muhammad Ishrat Husain, Nicole Ledwos, Elise Fellows, Jenna Baer, Joshua D. Rosenblat, Joshua D. Rosenblat, Daniel M. Blumberger, Daniel M. Blumberger, Benoit H. Mulsant, Benoit H. Mulsant, David J. Castle, David J. Castle   +12 more
doaj   +1 more source